XML 53 R40.htm IDEA: XBRL DOCUMENT v3.19.2
Disclosure about Fair Value of Financial Instruments (Tables)
6 Months Ended
Jun. 30, 2019
Fair Value Disclosures [Abstract]  
Carrying Amounts and Estimated Fair Values of Financial Instruments
The carrying amounts and estimated fair values of our financial instruments are as follows (in thousands):
 
 
June 30, 2019
 
December 31, 2018
 
 
Carrying Amount
 
Fair Value
 
Carrying Amount
 
Fair Value
Financial assets:
 
 
 
 
 
 
 
 
Mortgage loans receivable
 
$
264,398

 
$
274,116

 
$
249,071

 
$
257,337

Other real estate loans receivable
 
104,596

 
105,706

 
81,268

 
82,742

Equity securities
 
11,860

 
11,860

 
11,286

 
11,286

Cash and cash equivalents
 
268,666

 
268,666

 
215,376

 
215,376

Restricted cash
 
91,052

 
91,052

 
100,753

 
100,753

Foreign currency forward contracts, interest rate swaps and cross currency swaps
 
91,290

 
91,290

 
94,729

 
94,729

 
 
 
 
 
 
 
 
 
Financial liabilities:
 
 
 
 
 
 
 
 
Unsecured revolving credit facility and commercial paper note program
 
$
1,869,188

 
$
1,869,188

 
$
1,147,000

 
$
1,147,000

Senior unsecured notes
 
10,606,106

 
11,026,259

 
9,603,299

 
10,043,797

Secured debt
 
2,675,507

 
2,737,838

 
2,476,177

 
2,499,130

Foreign currency forward contracts, interest rate swaps and cross currency swaps
 
32,249

 
32,249

 
71,109

 
71,109

 
 
 
 
 
 
 
 
 
Redeemable OP unitholder interests
 
$
121,476

 
$
121,476

 
$
103,071

 
$
103,071


Summary of Items Measured at Fair Value on a Recurring Basis The following summarizes items measured at fair value on a recurring basis (in thousands):
 
 
Fair Value Measurements as of June 30, 2019
 
 
Total
 
Level 1
 
Level 2
 
Level 3
Equity securities
 
$
11,860

 
$
11,860

 
$

 
$

Foreign currency forward contracts, interest rate swaps and cross currency swaps, net asset (liability)(1)
 
59,041

 

 
59,041

 

Redeemable OP unitholder interests
 
121,476

 

 
121,476

 

Totals 
 
$
192,377

 
$
11,860

 
$
180,517

 
$

(1) Please see Note 12 for additional information.